The newly FDA-approved treatment, Abecma (ide-cel) CAR T Therapy, has been a popular topic of myeloma-based meetings and articles in recent months. So what will make this upcoming event in the Myeloma Crowd Community any different?
We wanted to take a more basic approach when considering the CAR T therapy. We will explore practical questions surrounding CAR T therapy such as:
And to answer these questions we have multiple myeloma specialist, Dr. Nina Shah from UCSF Health. With experience in the CAR T clinical trials, Dr. Shah has a unique perspective on the treatment and will be able to share her knowledge with us in a clear and precise way.
Don't miss the chance to ask an expert your questions about this new and upcoming therapy. It could be a game-changer in your myeloma journey!
about the author
Audrey joined the Myeloma Crowd as the Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.